AUG 25 2026
Xspray Pharma AB — Dasynoc (dasatinib)
for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)
Accepted FEB 26 2026.
About
Chronic myelogenous leukemia is a cancer of the blood and bone marrow that affects myeloid tissue. Dasynoc (dasatinib) is a tyrosine kinase inhibitor that blocks specific proteins that signal cancer cells to grow and divide. By interfering with these growth signals, the drug may help control the progression of the disease.
Pivotal trial
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Dasynoc
- FDA Rejects Dasatinib (Dasynoc) for Leukemia - Oncology News Central
- Xspray's Dasynoc is latest drug shot down by FDA due to manufacturing issues - FirstWord Pharma
- FDA Issues CRL to NDA for Dasynoc in CML and ALL - Targeted Oncology
- A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc - Endpoints News
- Xspray Pharma's CEO: "XS003 shows that we are building a powerhouse – Dasynoc is just the beginning" - Biostock